← Back to Search

Acetazolamide for Cerebral Vasospasm

Phase 4
Waitlist Available
Led By Azam Ahmed, MD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre and post perfusion during imaging procedure, up to an hour
Awards & highlights

Study Summary

This trial will test a new technique to see if it can detect early signs of a defect in cerebral autoregulation.

Eligible Conditions
  • Cerebral Vasospasm
  • Brain Aneurysm

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1-14 during the hospitalization
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1-14 during the hospitalization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants Who Develop Delayed Cerebral Vasospasm
Secondary outcome measures
Percent Change in Left Hemisphere Brain Imaging Maps
Percent Change in Right Hemisphere Brain Imaging Maps
Relative Percent Change in Cerebral Blood Flow

Side effects data

From 2022 Phase 4 trial • 11 Patients • NCT03377049
9%
External Ventricular Drainage infection
9%
Hydrocephalus
9%
Pulmonary edema
9%
Cardiomyopathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Acetazolamide Challenge

Trial Design

1Treatment groups
Experimental Treatment
Group I: Acetazolamide ChallengeExperimental Treatment1 Intervention
Participants entered into the study as a cohort, will because of their participation, undergo only two additional digital subtraction angiogram (DSA) imaging acquisitions. These will be done in conjunction with their standard diagnostic DSA evaluation and consist of two CBCTPs, one before and one after administration of 1 g acetazolamide through a peripheral IV line. Each CBCTP will require administration of 75-100 mL iodinated contrast medium also through an intravenous line. Neither of these imaging studies will be used for clinical decision making, but would be processed and evaluated at later date for a formal analysis of the results. Following completion of diagnostic imaging subjects will receive the usual standard of care for treatment of their ruptured aneurysm i.e. endovascular embolization or open surgical clipping.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetazolamide
2011
Completed Phase 4
~2910

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor
1,189 Previous Clinical Trials
3,169,535 Total Patients Enrolled
Azam Ahmed, MDPrincipal InvestigatorUniversity of Wisconsin, Madison
1 Previous Clinical Trials
100 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
CirculationJournal
Heart Disease and Stroke Statistics—2012 Update
Writing Group Members, Véronique L. Roger, Alan S. Go, Donald M. Lloyd-Jones, Emelia J. Benjamin, Jarett D. Berry, William B. Borden, et al.. 2012. “Heart Disease and Stroke Statistics—2012 Update”. Circulation. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/cir.0b013e31823ac046.
clinicaltrials.govStudy
Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm
2019. "Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03377049.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top